Smith & Nephew plcの収益品質スコアは/です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
Smith & Nephew plcはいつ収益を報告しますか?
Smith & Nephew plcの次の収益報告は2026-05-31に予定されています
Smith & Nephew plcの予想収益はいくらですか?
ウォール街のアナリストによると、Smith & Nephew plcの予想収益は$です。
Smith & Nephew plcは収益予想を上回りましたか?
Smith & Nephew plcの最近の収益は$で、予想を。
主要データ
前終値
$31.59
始値
$31.66
当日レンジ
$31.21 - $31.9
52週レンジ
$23.91 - $38.79
取引高
315.6K
平均取引高
886.7K
配当利回り
--
1株当たり利益(TTM)
1.43
時価総額
$13.4B
Smith & Nephew SNATS, Inc.とは何ですか?
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. The company is headquartered in Watford, Hertfordshire and currently employs 16,988 full-time employees. The firm is engaged in developing, manufacturing, marketing, and selling medical devices and services. The company is focused on the repair, regeneration, and replacement of soft and hard tissue. The firm's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.